Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
INCY Stock Forecast 2026-2027
$92.54
Current Price
$18.42B
Market Cap
Buy 12
Hold 12
Sell 2
Wall St Analyst Ratings
Distance to INCY Price Targets
+45.9%
To High Target of $135.00
+18.9%
To Median Target of $110.00
-23.3%
To Low Target of $71.00
INCY Price Momentum
-4.7%
1 Week Change
-8.5%
1 Month Change
+36.4%
1 Year Change
-6.3%
Year-to-Date Change
-17.6%
From 52W High of $112.29
+72.8%
From 52W Low of $53.56
📊 TOP ANALYST CALLS
Did INCY Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Incyte is one of their latest high-conviction picks.
Latest INCY Stock Price Targets & Analyst Predictions
Based on our analysis of 40 Wall Street analysts, INCY has a neutral consensus with a median price target of $110.00 (ranging from $71.00 to $135.00). The overall analyst rating is Buy (7.4/10). Currently trading at $92.54, the median forecast implies a 18.9% upside. This outlook is supported by 12 Buy, 12 Hold, and 2 Sell ratings.
The most optimistic forecast comes from Mitchell S. Kapoor at HC Wainwright & Co., projecting a 45.9% upside. Conversely, the most conservative target is provided by Jessica Fye at JP Morgan, suggesting a 23.3% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
INCY Analyst Ratings
12
Buy
12
Hold
2
Sell
INCY Price Target Range
Low
$71.00
Average
$110.00
High
$135.00
Current: $92.54
Latest INCY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for INCY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 9, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Reiterates | $135.00 |
| Mar 5, 2026 | Evercore ISI Group | Maneka Mirchandaney | In-Line | Maintains | $110.00 |
| Feb 18, 2026 | Barclays | Etzer Darout | Overweight | Maintains | $117.00 |
| Feb 11, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Reiterates | $135.00 |
| Feb 11, 2026 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $92.00 |
| Feb 11, 2026 | Wells Fargo | Derek Archila | Equal-Weight | Maintains | $101.00 |
| Feb 11, 2026 | Stifel | Stephen Willey | Buy | Maintains | $120.00 |
| Feb 6, 2026 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $110.00 |
| Feb 5, 2026 | HC Wainwright & Co. | Mitchell S. Kapoor | Buy | Initiates | $135.00 |
| Feb 4, 2026 | Barclays | Etzer Darout | Overweight | Maintains | $116.00 |
| Jan 20, 2026 | Wells Fargo | Derek Archila | Equal-Weight | Downgrade | $107.00 |
| Jan 13, 2026 | TD Cowen | Marc Frahm | Buy | Maintains | $128.00 |
| Jan 6, 2026 | Morgan Stanley | Vikram Purohit | Equal-Weight | Maintains | $94.00 |
| Dec 8, 2025 | Wells Fargo | Derek Archila | Overweight | Maintains | $116.00 |
| Dec 8, 2025 | Morgan Stanley | Vikram Purohit | Equal-Weight | Maintains | $92.00 |
| Dec 8, 2025 | Mizuho | Salim Syed | Outperform | Upgrade | $121.00 |
| Nov 24, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $115.00 |
| Nov 4, 2025 | Piper Sandler | Allison Bratzel | Overweight | Maintains | $102.00 |
| Nov 3, 2025 | Guggenheim | Michael Schmidt | Buy | Upgrade | $125.00 |
| Oct 29, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $101.00 |
Incyte Corporation (INCY) Competitors
The following stocks are similar to Incyte based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Incyte Corporation (INCY) Financial Data
Incyte Corporation has a market capitalization of $18.42B with a P/E ratio of 15.0x. The company generates $5.14B in trailing twelve-month revenue with a 25.0% profit margin.
Revenue growth is +27.8% quarter-over-quarter, while maintaining an operating margin of +25.6% and return on equity of +29.9%.
Valuation Metrics
Market Cap
$18.42B
Enterprise Value
$15.58B
P/E Ratio
15.0x
PEG Ratio
0.3x
Price/Sales
3.7x
Growth & Margins
Revenue Growth (YoY)
+27.8%
Gross Margin
+92.0%
Operating Margin
+25.6%
Net Margin
+25.0%
EPS Growth
+48.7%
Financial Health
Cash/Price Ratio
+19.4%
Current Ratio
3.3x
Debt/Equity
1.1x
ROE
+29.9%
ROA
+13.6%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Incyte Corporation (INCY) Business Model
About Incyte Corporation
What They Do
Develops targeted therapeutics for complex diseases.
Business Model
Incyte Corporation operates as a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics. It generates revenue primarily through the sale of its key products, including JAKAFI and OPZELURA, and earns additional income via royalties from partnered products such as Jakavi and Olumiant.
Additional Information
Founded in 1991 and based in Wilmington, Delaware, Incyte has a diversified portfolio targeting hematology, oncology, inflammation, and autoimmunity. The company operates globally, advancing a pipeline of candidates to meet urgent medical needs in these areas.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
2,844
CEO
Mr. William J. Meury
Country
United States
IPO Year
1993
Website
www.incyte.comIncyte Corporation (INCY) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mar 12, 2026
By Zacks Equity Research
Realtime BLOG
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz
Incyte's Zynyz wins EU approval with chemotherapy for advanced anal cancer, marking the first systemic treatment for this indication.
Mar 09, 2026
By Zacks Equity Research
Analyst Blog
Latest News
Incyte Corporation (INCY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript
4 days ago
Quick Summary
Incyte Corporation (INCY) presented at the Barclays 28th Annual Global Healthcare Conference, discussing its latest developments and strategies in the healthcare sector.
Why It Matters
Incyte's presentation at a major healthcare conference can signal new developments or strategic shifts, impacting stock performance and investor sentiment in the biotech sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Incyte (INCY) reported earnings 30 days ago. Investors should monitor upcoming developments and market reactions for insights on the stock's future performance.
Why It Matters
Earnings reports can influence stock performance, impacting investor sentiment and pricing. Upcoming developments or forecasts may affect Incyte's stock trajectory.
Source: Zacks Investment Research
Market Sentiment:
Negative
Incyte Corporation (INCY) Presents at Leerink Global Healthcare Conference 2026 Transcript
5 days ago
Quick Summary
Incyte Corporation (INCY) presented at the Leerink Global Healthcare Conference 2026, providing updates on its developments and strategies in the healthcare sector.
Why It Matters
Incyte's presentation at a major healthcare conference can indicate upcoming innovations or partnerships, potentially impacting stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Incyte's Zynyz has received EU approval for use with chemotherapy in advanced anal cancer, becoming the first systemic treatment approved for this condition.
Why It Matters
Incyte's Zynyz gaining EU approval for advanced anal cancer opens new market opportunities and potential revenue streams, signaling growth prospects for the company.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Incyte received European Commission approval for Zynyz (retifanlimab) to treat first-line advanced squamous cell carcinoma of the anal canal.
Why It Matters
European approval of Zynyz expands Incyte's market potential, enhancing revenue prospects and signaling strong product viability, which may boost investor confidence and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
13 days ago
Quick Summary
Incyte Corporation (INCY) presented at the TD Cowen 46th Annual Health Care Conference, sharing updates on its developments and strategies.
Why It Matters
Incyte's presentation may signal strategic updates or new developments that could impact its stock performance and investor sentiment in the healthcare sector.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About INCY Stock
What is Incyte Corporation's (INCY) stock forecast for 2026?
Based on our analysis of 40 Wall Street analysts, Incyte Corporation (INCY) has a median price target of $110.00. The highest price target is $135.00 and the lowest is $71.00.
Is INCY stock a good investment in 2026?
According to current analyst ratings, INCY has 12 Buy ratings, 12 Hold ratings, and 2 Sell ratings. The stock is currently trading at $92.54. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for INCY stock?
Wall Street analysts predict INCY stock could reach $110.00 in the next 12 months. This represents a 18.9% increase from the current price of $92.54. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Incyte Corporation's business model?
Incyte Corporation operates as a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics. It generates revenue primarily through the sale of its key products, including JAKAFI and OPZELURA, and earns additional income via royalties from partnered products such as Jakavi and Olumiant.
What is the highest forecasted price for INCY Incyte Corporation?
The highest price target for INCY is $135.00 from Mitchell S. Kapoor at HC Wainwright & Co., which represents a 45.9% increase from the current price of $92.54.
What is the lowest forecasted price for INCY Incyte Corporation?
The lowest price target for INCY is $71.00 from Jessica Fye at JP Morgan, which represents a -23.3% decrease from the current price of $92.54.
What is the overall INCY consensus from analysts for Incyte Corporation?
The overall analyst consensus for INCY is neutral. Out of 40 Wall Street analysts, 12 rate it as Buy, 12 as Hold, and 2 as Sell, with a median price target of $110.00.
How accurate are INCY stock price projections?
Stock price projections, including those for Incyte Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 9:48 PM UTC